21 ．Influenza Virus Research Center

Itagaki T, Katsushima F, Katsushima Y, Nagai Y, andNishimura H. Evaluation of a new rapid antigen test1)

Wada, T., Morishima, T., Okumura, A., Tashiro,M.,

using immunochromatography for detection of human

Hosoya, M., Shiomi, M., Okuno, Y.: Differences in

metapneumovirus in comparison with real-time PCR

clinical manifestations of influenza-associatedassay. J Clin Microbiol. 47, 2981-2984 (2009)

encephalopathy by age. Microbiol. Immunol. 53:2)

S, Mizuta K, Itagaki T, Nishimura H, and Matsuzaki Y.

Thongratsaku, S., Songserm, T., Poolkhet, C., Kondo,

Development and evaluation of a whole virus-based

S., Yagi, H. Hiramatsu, H., Tashiro, M., Okada, H.,

enzyme-linked immunosorbent assay for the detection ofKato,K., Suzuki, Y. :Determination of N-linked

human metapneumovirus antibodies in human sera. J

sialyl-sugar chains in the lungs of domestic cats andVirol Methods. 164, 24-29 (2010)

5)

7)

Muraki Y, Furukawa T, Kohno Y, Matsuzaki Y, Takashita
E, Sugawara K, and Hongo S. Influenza C virus NS1

2:28-36, 2009.

protein up-regulates the splicing of viral mRNAs. J Virol.

Tashiro, M., McKimm-Breschkin, J., Saito, T.,

84, 1957-1966 (2010)10) Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh

F.:Surveillance for neuraminidase inhibitor-resistantK, Sugawara K, Takashita E, Itagaki T, Katsushima Y,

influenza viruses in Japan, 1996-2007.Antiviral

Ujike M, Obuchi M, Odagiri T, and Tashiro M. A

Therapy 14: 751-761, 2009

two-year survey of the oseltamivir-resistant influenzaWHO/OIE/FAO H5N1

Evolution

A(H1N1) virus in Yamagata, Japan and the clinical

Working Group; Brown, I. H., Capua, I., Cattoli, G.,

effectiveness of oseltamivir and zanamivir. Virol J. 7, 53

Chen, H., Cox, N., Davis, T., Donis, R. O., Fouchier,(2010)

R. A. M. Garten, R., Guan, Y., Kawaoka, Y., Mackenzie,11) Ujike M, Shimabukuro K, Mochizuki K, Obuchi M,

J., McCauley, J., Mumford, E., Olsen, C., Perdue, M.,

Kageyama T, Shirakura M, Kishida N, Yamashita K,Russell, C. A., Smith, C., Smith, D., Smith,G. J. D., Shu,

Horikawa H, Kato Y, Fujita N, Tashiro M, Odagiri T;

Y., Tashiro, M., Vijaykrishna, D.,

Working Group for Influenza Virus Surveillance in Japan.

Webster, R. :Continuing progress towards a unified

Oseltamivir-resistant influenza viruses A (H1N1) during

nomenclature for the highly pathogenic H5N1 avian

2007-2009 influenza seasons, Japan.

influenza viruses: divergence of clade 2.2 viruses. J.

16:926-935（2010）

Emerg Infect Dis.

Influenza. Resp. Viral Infect. 3: 59-62, 2009.

12) .Ikeno D., Kimachi K., Kudo Y., Goto S., Itamura S.,

Sriwilaijaroen, N., Wilairat, P., Hiramatsu, H.,

Odagiri T., Tashiro M., Kino Y. A prime-boost

Takahashi, T., Suzuki, T., Ito, M., Ito, Y., Tashiro, M.,vaccination of mice with heterologous H5N1 strains.

Suzuki, Y.:Mechanisms of the action of

Vaccine 27, 3121-3125 (2009)

povidone-iodine against human and avian influenza

6)9)avian influenza virus (H5N1). Open Glycoscience ,Klimov,A., Macken, C., Zambon, M., Hayden,4)

Okamoto M, Sugawara K, Takashita E, Muraki Y, Hongo

83-88, 2009

dogs in Thailand susceptible to the highly pathogenic3)

8)13) Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A,

A viruses: its effects on hemagglutination andTakagi H, Odagiri T, Sata T, Tashiro M, Kobayashi K

sialidase activities. Virology Journal. 6:124, 2009

Protective immunity afforded by inactivated H5N1

Bertozzi, S., Kelso, A., Tashiro, M., Savy, V., Farrar,(NIBRG-14) vaccine requires antibodies against bothJ., Osterholm, M., Jameel, S., Muller, C.P. :Pandemic

hemagglutinin and neuraminidase in mice. J Infect Dis.

flu: from front lines. Nature 461; 20-21, 2009

199(11):1629-37, 2009 .

Matsuzaki Y, Takashita E, Okamoto M, Mizuta K,14) Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike
1

M, Odagiri T, Iwata M, Toyozawa T, Tashiro M.

20) Ishii K, Hasegawa H, Nagata N, Ami Y, Fukushi S,

Isolation of oseltamivir-resistant influenza A/H1N1 virus

Taguchi F, Tsunetsugu-Yokota Y.

of different origins in Yokohama City, Japan, during theagainst severe acute respiratory syndrome

2007-2008 influenza season. Jpn J Infect Dis. 62(1):83-6,(SARS)-coronavirus spike is highly effective for the2009

protection of mice in the murine SARS model. Microbiol

15) Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama
JI, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura
SI, Chiba J, Kurata T, Sata T, Hasegawa H.

Neutralizing antibodyImmunol. 2009 Feb;53(2):75-82.
21) Kataoka M, Yamamoto A, Ochiai M, Harashima A,Induction

Nagata N, Hasegawa H, Kurata T, Horiuchi Yof cross-protective immunity against influenza A virus

Comparison of acellular pertussis-based combination

H5N1 by an intranasal vaccine with extracts ofvaccines by Japanese control tests for toxicities andmushroom mycelia.

laboratory models for local reaction Vaccine 2009

J Med Virol. 2010

Jan;82(1):128-37.

27,1881-1888

16) Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG,

22) Iizuka I, Saijo M, Shiota T, Ami Y, Suzaki Y, Nagata N,Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A,Hasegawa H, Sakai K, Fukushi S, Mizutani T, Ogata M,

Odagiri T, Smith D, Russell C, Tashiro M, Webby R,Nakauchi M, Kurane I, Mizuguchi M, Morikawa

Wood J, Ye Z, Zhang W; Writing Committee of theS.Loop-mediated isothermal amplification-based

World Health Organization Consultation on Northern

diagnostic assay for monkeypox virus infections.

Hemisphere Influenza Vaccine Composition for

Med Virol. 2009 Jun;81(6):1102-8.

2009-2010.

Epidemiological, antigenic and geneticJ23) Hayasaka D, Nagata N, Fujii Y, Hasegawa H, Sata T,

characteristics of seasonal influenza A(H1N1), A(H3N2)

Suzuki R, Gould A E, Takashima I, Koike A Mortality

and B influenza viruses: basis for the WHO

following peripheral infection with Tick-borne

recommendation on the composition of influenza

encephalitis virus results from a combination of central

vaccines for use in the 2009-2010 Northern Hemispherenervous system pathology, systemic inflammatory andseason.

stress response Virology 2009 Jul 20;390(1):139-50.

Vaccine. 2010 Feb 3;28(5):1156-67. Epub2009 Dec 9.

Epub 2009 May 24.

17) Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K,24) Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa

Tochihara S, Itamura S, Odagiri T, Tashiro M, Okada K,H, Iizuka I, Shiota T, Sakai K, Ogata M, Fukushi S,Miyazaki C, Ueda K.

Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S.

Immunogenicity of an

inactivated adjuvanted whole-virion influenza A (H5N1,Virulence and pathophysiology of the Congo Basin andNIBRG-14) vaccine administered by intramuscular orWest African strains of monkeypox virus in nonhumansubcutaneous injection.

primates J Gen Virol

Microbiol Immunol. 2010

Feb;54(2):81-8.
18) Takahashi H, Kitagawa Y, Maeda-Satoh M, Hasegawa H,

2009 Sep;90(Pt 9):2266-71. Epub

2009 May 27.
25) Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M,Sawa H, Sata T. Monoclonal Antibody and siRNAs for

Momose H, Masumi A, Ami Y, Hasegawa H, Hall W. W,

Topoisomerase ISuppress Telomerase Activity.

Tsujimoto H, Hamaguchi I, Yamaguchi K Identification

Hybridoma (Larchmt). 2009 Feb;28(1):63-5.

of Cancer Stem Cells in a Tax-transgenic (Tax-Tg)19) Hasegawa H*, Ichinohe T, Ainai A, Tamura S, Kurata T.

Mouse Model of Adult T- Cell Leukemia / lymphoma

Development of an inactivated mucosal vaccine for(ATL). Blood 2009 Sep 24;114(13):2709-20. Epub 2009

H5N1 influenza virus. Therapeutic and Clinical Risk

Jul 7.

Management 2009 Feb;5(1):125-32.

26) Tobiume M, Sato Y, Katano H, Nakajima N, Tanaka K,
2

Noguchi A, Inoue S, Hasegawa H, Iwasa Y, Tanaka J,Hayashi H, Yoshida S, Kurane I, Sata T. Rabies virusdissemination in neural tissues of autopsy cases due torabies imported into Japan from the Philippines:
immunohistochemistry. Pathol Int. 2009
Aug;59(8):555-66.
27) Takahashi H, Ohtaki N, Maeda-Sato M, Tanaka M,Tanaka K, Sawa H, Ishikawa T, Takamizawa A, Takasaki
T, Hasegawa H, Sata T, Hall WW, Kurata T, Kojima A.
Effects of the number of amino acid residues in thesignal segment upstream or downstream of the NS2B-3
cleavage site on production and secretion of prM/M-E
virus-like particles of West Nile virus. Microbes Infect.
2009 Nov;11(13):1019-28. Epub 2009 Aug 7.
28) Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, TsujiT, Ainai A, Sata T, Okamoto T, Hall W.W, Sawa H,Hasegawa H Inhibition of the SDF-1α-CXCR4 axis by
the CXCR4 antagonist AMD3100 suppresses themigration of cultured cells from ATL patients and murine
lymphoblastoid cells from HTLV-I Tax transgenic mice.
Blood 2009 Oct 1;114(14):2961-8. Epub 2009 Aug 5.
29) Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.
PolyI:polyC12U adjuvant-combined intranasal vaccine
protects mice against highly pathogenic H5N1 influenza
virus variants. Vaccine. 2009 Oct 23;27(45):6276-9.
30) Kitagawa Y, Maeda-Sato M, Tanaka K, Tobiume M,Sawa H, Hasegawa H, Kojima A, Hall WW, Kurata T,Sata T, Takahashi H. Covalent bonded Gag multimers inhuman immunodeficiency virus type-1 particles.
Microbiol Immunol. 2009 Nov;53(11):609-20.
31) Hayasaka D, Nagata N, Hasegawa H, Sata T, TakashimaI, Koike S. Early Mortality Following Intracerebral
Infection with Tick-Borne Encephalitis Virus Oshima
Strain in a Mouse Model. J Vet Med Sci. 2009 Dec 9.
32) Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama
J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S,Chiba J, Kurata T, Sata T, Hasegawa H. Induction ofcross-protective immunity against influenza A virus
H5N1 by an intranasal vaccine with extracts ofmushroom mycelia. J Med Virol. 2010 Jan;82(1):128-37.
3